Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combined Treatment Approach Increases Survival In Prostate Cancer

05.04.2005


New study shows combination of radiotherapy and hormone therapy extends life expectancy.



Men with prostate cancer treated with the combined therapies had a significantly higher chance of living for more than 10 years than those on radiotherapy alone. This was one of the main results published today in the International Journal of Radiation Oncology, Biology and Physics (IJROBP) by the independent Radiation Oncology Group (RTOG).

Goserelin belongs to a class of drugs called Luteinizing Hormone-Releasing Hormone agonist (LHRHa). This therapeutic modality works by inhibiting the production of the male hormone, testosterone.


The research also showed that by treating men with goserelin and radiotherapy, the chances of preventing the disease from coming back were improved by 60 percent compared to men who only received radiotherapy.1

Another study published this month in the British Journal of Urology International (BJUi) confirmed that these benefits were not seen in all LHRHas. Experts examined all LHRHas medications, but goserelin has been proven to be the only LHRHa providing proven benefit in terms of delaying progression and improving survival.

Mr Amir Kaisary, Consultant Urologist, Royal Free Hospital, London believes the RTOG’s publication is a major step forward in increasing the amount of attention being given to prostate cancer, which has always struggled to achieve the levels of public awareness of some other cancers.

‘Studies, such as the one published today in the IJROBP, are proving that surgical castration and radiotherapy are not the only treatments available for men with prostate cancer. An increasing amount of evidence shows that hormonal therapy, used either alone or with radiotherapy, offers significant benefits for men with prostate cancer, when offered in the appropriate patients.’

The study published in the IJROBP observed nearly 1,000 men with locally advanced prostate cancer over a 10 year period. The aim of the research was to determine how effective goserelin was when used with radiotherapy to treat men with locally advanced prostate cancer. This group of prostate cancer patients is where the cancer is no longer contained within the prostate gland as at the early stages of the disease.

The Department of Health has recognised the benefits of hormonal therapies because of studies such as the one published in the IJROBP. It has issued guidelines supporting the treatment of men with locally advanced prostate cancer using radiotherapy and a hormonal therapy. Anti-androgens are another type of hormonal therapy which can also be used to treat locally advanced prostate cancer. Anti-androgens block the biochemical transformation of androgens (the main one is testosterone) to the active form which stimulate the growth of prostate cancer tumours. Anti-androgens are increasingly being used by clinicians because they do not affect men’s physical strength, sexual interest or increase the risk of bone fractures. These are side effects which are associated with LHRHa therapy.

It is important that men with prostate cancer, when possible, are fully informed about the different side effects and can discuss with their doctor which treatment is the most suitable for their lifestyle and individual needs.

Tara Breen | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>